Save the date for our next Essential Tremor Support Group meeting which is scheduled for Saturday, April 3rd, from 1:00-3:00 p.m. via Zoom. Our speaker and topic will be announced shortly; and we do hope you’ll plan to join us!

Saturday, February 6, 2021
1:00 – 3:00 p.m.
Virtual Meeting via Zoom

Meet Biotech Company Praxis…
and learn about Investigational Drug PRAX-944

presented by Gabriel Belfort M.D., Ph.D. and Lisa Huang, Ph.D.

At this virtual meeting, you will learn about Praxis, a biotechnology company studying an investigational treatment for Essential Tremor. PRAX-944 belongs to a new class of drugs called T-type calcium channel blockers. It has been shown to be effective in animal models of Essential Tremor by blocking calcium channels that are essential to the rhythmic brain activity that causes tremor activity. If PRAX-944 can similarly block T-type calcium channels in patients with ET, it is possible that the abnormal rhythmic activity in the brain – and the subsequent tremors – may improve! Studies with PRAX-944 in ET patients have been initiated. You won’t want to miss this meeting to learn more!

Gabriel Belfort, M.D., Ph.D., is a Senior Medical Director at Praxis and is responsible for the design, conduct, and data analysis of studies in the PRAX-944 Essential Tremor program. He has been in the industry for eight years and with Praxis for two. He received an M.D. and a Ph.D. from Boston University, residency training in neurology from the Beth Israel Deaconess Medical Center, and postdoctoral training from MIT. Gabi was involved in the development of Brexanolone, now FDA approved for the treatment of post-partum depression.

Lisa Huang, Ph.D. is the commercial lead for the PRAX-944 Essential Tremor program. She has been in the industry for eight years, where she founded a number of biotechs, such as Magenta, Gemini Therapeutics, and Q32 Bio Inc. to address diseases with high clinical need. A human geneticist by training, Lisa obtained her PhD Degree from Johns Hopkins.

To register or request information, email Helen Moser or submit the form below.

The CT essential tremor support group is sponsored by

Whether it’s to be in person or via Zoom …that unfortunately is still the question! But in either event, we do hope you’ll plan to join us from 1:00 – 3:00 p.m. on Saturday, February 6th for our next CT Essential Tremor Support Group meeting. Details will be announced shortly.

Saturday, October 3, 2020
1:00 – 3:00 p.m.
Virtual Meeting via Zoom

Updates on Essential Tremor
presented by Movement Disorder Neurologist Dr. Leon Meytin

At this virtual meeting, Dr. Meytin will discuss some of the new updates in essential tremor, including several clinical trials currently ongoing, as well as recently published data on non-invasive treatment for essential tremor.

Dr. Leon Meytin, MD, a Board Certified Neurologist, is a fellowship trained Movement Disorder Specialist at Hartford Healthcare. After graduating from West Virginia University School of Medicine, Dr. Meytin completed his neurology residency at Thomas Jefferson University in Philadelphia, PA, followed by a Movement Disorders Fellowship at Mount Sinai Beth Israel in New York, NY.

Dr. Meytin was recently hired by Hartford Healthcare to start a Movement Disorders Center in Stamford, CT as part of Hartford Healthcare’s comprehensive Chase Family Movement Disorders Center. He believes in the holistic approach to treatment, including utilizing physical/occupational therapy, exercise, acupuncture, and social work to treat the entirety of the patient. A member of the American Academy of Neurology and Movement Disorder Society, Dr. Meytin is also fluent in Russian.

Inquiries are invited!
Registration is required no later than noon on Wednesday, September 30th!

To register or request information, email Helen Moser or submit the form below.

The CT essential tremor support group is sponsored by

Whether it’s to be in person or via Zoom …that is the question! But in either case, please plan to join us from 1:00 – 3:00 p.m. on Saturday, October 3rd for our next Essential Tremor Support Group meeting. We’ll get details to you as soon as possible.

Saturday, August 1, 2020
1:00 – 3:00 p.m.
Virtual Meeting via Zoom

How New Drugs Are Developed, plus an
Update on an ET-specific drug tested in Clinical Trial
presented by Tim Piser, PhD and Amber Trzeciak, MS

Tim Piser, PhD, is the Chief Scientific Officer at Cadent Therapeutics. Tim earned his PhD in pharmacology from the University of Minnesota. He has passionately pursued the discovery and development of neuroscience therapeutics for almost two decades in big pharma and in biotech, most notably at AstraZeneca and FORUM Pharmaceuticals. There, he led neuropharmacology teams and both NDA and nicotinic receptor drug discovery projects and product development teams from lead optimization through Phase 2 trials. Tim leverages collaborative scientific insight and quantitative translational pharmacology to find innovative paths to discover and develop potential breakthrough medicines.

Amber Trzeciak, MS, is Cadent’s Patient Partnership and Advocacy Manager, as well as Executive Assistant to its R&D Department.

At this virtual meeting, Tim and Amber will educate us on how new drugs are created and developed. They will also give us a history of Cadent’s CAD-1883 (an ET-specific drug that has been tested in clinical trial), together with an update on this trial.

Inquiries are invited!
Registration is required no later than noon on Wednesday, July 29th!

To register or request information, email Helen Moser or submit the form below.

The CT essential tremor support group is sponsored by